Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders
May 20, 2024 07:30 ET
|
Reunion Neuroscience Inc.
Reunion’s lead asset, RE104, is a potential best-in-class, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to...
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
May 02, 2024 06:30 ET
|
Reunion Neuroscience Inc.
Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with...
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
April 03, 2024 07:30 ET
|
Reunion Neuroscience Inc.
MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today...
Reunion Neuroscience Inc. to Participate in October Investor Conferences
October 05, 2023 07:30 ET
|
Reunion Neuroscience Inc.
WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic...
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
September 18, 2023 07:30 ET
|
Reunion Neuroscience Inc.
WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for...
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
August 01, 2023 09:03 ET
|
Reunion Neuroscience Inc.
TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
July 14, 2023 16:05 ET
|
Reunion Neuroscience Inc.
TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
July 13, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
June 29, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase...
Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact
June 01, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final...